PRECIGEN, INC.
In the published model solve dated 2026-Q2, anchored at $6.88, PRECIGEN, INC. (PGEN) is priced for today's economics sustained for ~40.0 years+. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Precigen just became a commercial company, winning full FDA approval in August 2025 for Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, and booking about $21.6 million of product revenue in its first full launch quarter. • The defining fact is the cash math: with about $56.7 million on hand plus Papzimeos receivables, management projects it can reach cash-flow breakeven by the end of 2026, a runway that depends entirely on the launch ramp holding. • The biggest ris
Is PGEN overvalued? See what's priced in →
195 institutional managers reported holding PGEN in 13F filings for the quarter ended 2026-03-31. Together they hold about 38% of the company; the top 10 hold 25%. 38 opened new positions that quarter. Held by BlackRock, State Street, Vanguard Group, among others. On the short side, 43.3M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (7.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PGEN's share count grew 78% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PGEN over the trailing three years: 2023: 8 buys totaling $2.62M; 2024: 2 buys totaling $20.05M; 2025: 7 buys totaling $236k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PGEN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-11 | -9.5% | +3.5% |
| 2023-08-10 | +31.0% | -23.0% |
| 2023-11-10 | -13.5% | +25.7% |
| 2024-03-20 | +3.6% | -4.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PGEN's latest 8-K filings: 2026-08-04 (items 2.02); 2026-06-24 (items 5.02, 5.07, 9.01); 2026-05-13 (items 2.02, 9.01); 2026-03-25 (items 2.02, 9.01); 2025-11-13 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.